What Is Ozempic Face Before and After?

“Ozempic face” describes the gaunt, hollow, prematurely aged facial appearance that can develop after significant weight loss on GLP-1 receptor agonist medications like semaglutide. The term was coined by the media rather than by physicians, but the underlying changes are real and measurable: studies using CT imaging have documented a median decrease of about 9% in total midfacial volume among patients on these drugs. What makes the “before and after” jarring is that the facial changes resemble aging that normally takes decades, compressed into months.

What Changes in the Face

The face stores fat in distinct pads that sit at different depths, and these pads do not shrink uniformly during weight loss. A radiographic study of patients on GLP-1 agonists found that superficial facial volume dropped by a median of 11%, while deeper volume decreased by about 7%. The superficial loss correlated with how much total weight a person lost, but the deep volume loss did not, suggesting that the deeper fat pads follow their own rules and may not respond predictably to the same degree of calorie deficit.¹ That same study estimated a loss of roughly 7% of facial volume for every 10 kilograms of body weight shed.

Specific fat pads take particularly dramatic hits. One volumetric analysis of five patients on Ozempic found the superficial temporal fat pad shrank by an average of about 42%, and the cheek fat pad shrank by nearly 70%.² Those are the fat deposits that give the midface its youthful contour, so losing them produces sunken temples, flattened cheeks, and a skeletal look around the eyes and jawline. The skin that once draped over that volume now has nothing underneath it, leading to sagging and deeper folds around the nose and mouth.

Beyond fat, the visible surface changes matter too. The skin itself can thin out and lose its structural support. Reviews describe a combination of collagen and elastin loss, muscle volume reduction, and excessive skin laxity that together produce the hallmark sagging and creasing.³ What makes this distinctive is that these features normally develop gradually over many years of aging. In Ozempic face, they appear in people who are far younger than you would expect to see that degree of facial deflation.

Why It Happens, and Whether the Drug Itself Is to Blame

The simplest explanation is that rapid, substantial weight loss causes dramatic facial volume loss, and GLP-1 receptor agonists happen to produce that kind of weight loss very effectively. This is not unique to Ozempic. Bariatric surgery has produced the same hollow facial appearance for decades, well before anyone heard of semaglutide. A systematic review of facial changes after massive weight loss found that most of the available research focused on surgical weight-loss patients, with only two papers even mentioning GLP-1 agonists.² The facial consequences look the same regardless of how the weight was lost.

That said, there is a more provocative question researchers are investigating: could the medication itself be doing something to the skin and fat tissue beyond what weight loss alone would explain? GLP-1 receptors have been found on fat-derived stem cells and on fibroblasts, the cells responsible for producing collagen in the skin.⁴ Some preclinical work has also found GLP-1 receptor expression in skin cells around hair follicles, hinting at a potential direct role in how the skin functions.⁵ Changes in adipose-derived stem cell behavior, collagen support, oxidative stress, and nutritional status have all been proposed as contributors to the skin changes seen in some patients.⁶

A critical review of the evidence concluded that the association between GLP-1 drugs and accelerated facial sagging is “robust and reproducible,” but that a drug-specific mechanism remains “biologically plausible, still-unproven.” The key gap is that no study has properly controlled for the speed and amount of weight loss as a confounding variable.⁷ In other words, researchers cannot yet separate what the drug might be doing to facial tissue from what rapid weight loss alone would do. Until someone designs a study that compares people who lost the same amount of weight at the same speed through different methods, this question stays open.

Who Gets Hit the Hardest

Not everyone who takes semaglutide or tirzepatide ends up looking gaunt. The degree of facial change varies considerably, and several risk factors make someone more vulnerable. A comprehensive literature review identified advanced age, a long history of obesity, rapid weight loss, poor hydration, and insufficient protein intake as the main predictors of more severe outcomes.⁸

Age matters a lot here because the face naturally loses collagen and elasticity over time. Someone who starts a GLP-1 medication at 55 with already-thinning skin has far less structural reserve to absorb the deflation than a 30-year-old. Similarly, someone who has been carrying significant excess weight for many years may have skin that has lost its ability to contract after being stretched for so long. Speed of loss also plays a role: the faster the fat disappears, the less time the skin has to adapt, which is one reason GLP-1 medications can produce more dramatic facial changes than slow, diet-based weight loss.

Nutritional status tends to be underappreciated. GLP-1 drugs suppress appetite so effectively that many users eat considerably less, and if their reduced intake falls short on protein, their body has fewer building blocks to maintain skin and muscle. Many providers now recommend thorough nutritional assessment and optimization before starting treatment, with a particular emphasis on adequate protein.⁹ Hydration matters too, since the skin’s plumpness depends partly on water content.

The Aging Paradox in Before-and-After Comparisons

One of the stranger findings in this area is how facial changes after weight loss create an unusual split between looking younger and looking older. Early research on perceived age after bariatric surgery found that patients who lost a mild amount of weight were seen as more youthful but less attractive, while patients who lost a large amount of weight were perceived as older yet somehow more attractive overall.¹⁰ This makes intuitive sense if you think about it: a little weight loss tightens the face subtly, while a lot of weight loss reveals bone structure and definition that reads as attractive even though the hollows and wrinkles code as older.

This paradox helps explain why “before and after” photos of Ozempic face can be so disorienting. The “before” photo often shows a face that looks smooth and full but somewhat shapeless. The “after” shows angular features and clearer bone structure, but with visible temple hollowing, deeper nasolabial folds, and skin that seems to drape loosely. Whether someone thinks the “after” looks better or worse depends heavily on the degree of loss, the person’s age, and which features the viewer focuses on. A jawline that emerges from under fullness can look striking; temples that cave in do not.

What Cosmetic Treatments Can Do

The cosmetic dermatology and plastic surgery fields have been scrambling to develop treatment protocols specifically for this patient population, and results from early studies are encouraging. The two main injectable approaches are hyaluronic acid fillers for immediate volume restoration and poly-L-lactic acid for longer-term collagen stimulation.

A real-world case series from Latin America treated 15 patients who had lost an average of about 18% of their body weight on GLP-1 medications, using a combination of both filler types. By 90 days, facial laxity scores dropped significantly, and nasolabial fold severity improved in 85% of those who had notable folds at the start. All patients reported aesthetic improvement, and 40% rated the result as “exceptional.”¹¹ A separate multicenter study tested a similar combined regimen, injecting hyaluronic acid into the cheekbones for immediate contour correction and poly-L-lactic acid into the lower face for gradual collagen rebuilding. Improvements in the cheek, jawline, and around the mouth were visible in clinical photography and lasted through nine months of follow-up, with no treatment-related adverse events reported.¹²

For people with more advanced changes, surgical options exist. A facelift combined with fat transfer is considered one of the most effective approaches. Fat is harvested from another part of the body through liposuction and injected into the face to restore lost volume while simultaneously tightening excess skin.¹³ This addresses both sides of the problem: the deflation and the laxity. The obvious downside is cost, recovery time, and the fact that surgical fat transfer results can be variable.

One important caveat applies to all of these treatments: the evidence base is still thin. A review of collagen biostimulators noted that while they have a biologically plausible rationale for addressing this kind of facial volume loss, no studies have directly enrolled patients with GLP-1-associated facial aging in controlled trials.¹⁴ The treatments being used are borrowed from general facial rejuvenation practice and adapted for this population, not designed from scratch for it.

The Weight-Regain Complication

Here is something that rarely makes it into the before-and-after conversation: what happens when someone stops the medication? Discontinuing GLP-1 drugs typically leads to regaining up to two-thirds of the lost weight.⁹ That means the gaunt facial appearance could partially reverse on its own as fat returns to the face. On the surface, that sounds like good news, but it creates a genuine clinical headache for anyone who had fillers or fat grafting done to correct the hollowness. If you received substantial cheek filler while thin and then your face fills out naturally from regained weight, you could end up with an overfilled look. Some clinicians now recommend discussing filler dissolution if and when GLP-1 medications are interrupted, to avoid ending up with excessive facial fullness from both the injected material and returning fat.

This puts patients in a difficult position. They might be unhappy with their gaunt face while on the medication, get cosmetic treatment, and then face a different cosmetic problem if they stop the drug. Planning for both scenarios is not something most patients are counseled on, and it is an area where the before-and-after framing becomes genuinely misleading: the “after” is not a stable endpoint if the medication is not continued indefinitely.

How the Research Has Been Measured

Measuring facial changes objectively is harder than it sounds, and the tools researchers use affect how confident you should be in the numbers. The gold standard would be serial CT scans, which is what the midfacial volume study used. But most patients are not going to get repeated CT scans of their face for cosmetic tracking. Three-dimensional laser scanning has been tested as a less invasive alternative, with early validation work comparing it to MRI-measured cheek fat changes. That research found laser scanning has promise for tracking surface volume changes but needs further validation in larger groups.¹⁵ Another approach is simply measuring distances between facial landmarks before and after weight loss, as one study did with 23 bariatric surgery patients at baseline and six months later.¹⁶

The practical limitation is that most of the dramatic before-and-after photos circulating online are uncontrolled. They are taken under different lighting, at different angles, sometimes years apart. They tell a visual story that is real in the sense that the person’s face genuinely changed, but they cannot isolate what caused the change or how much of it was the medication versus aging, weight loss from any cause, or even the photography itself. The clinical studies are more reliable, but as that systematic review found, the GLP-1-specific data is still sparse. Most evidence about facial changes after major weight loss comes from bariatric surgery patients, and researchers are extending those findings to the GLP-1 population somewhat by analogy.

A Media Term, Not a Medical Diagnosis

“Ozempic face” was created and popularized by news outlets, and researchers have noted it likely represents a transient trend rather than new medical terminology or a previously unrecognized side effect.⁹ Facial volume loss after significant weight loss has always existed. What changed is that millions of people are now losing large amounts of weight on the same class of drug, many of them doing so publicly or at least visibly enough that the pattern became culturally recognizable. The branding of it as “Ozempic face” gave people a name for something they were seeing, which made it feel new even though it was not.

That branding has had commercial consequences. Sales of anti-obesity medications have surged, with Ozempic alone accounting for about $14 billion in revenue in 2023. The coining of “Ozempic face” has created an adjacent market: food and beverage companies have developed dietary supplements targeting the effect, and skincare companies have positioned their collagen treatments and fillers as solutions to it.⁹ Whether those products deliver meaningful results is a separate question from whether they sell well, and the catchy label has been more useful for marketing than for medicine.

Younger Patients and a Different Risk Profile

GLP-1 medications are increasingly prescribed to adolescents for obesity and type 2 diabetes, which raises the question of whether younger patients face the same facial consequences. So far, the answer seems to be no, or at least not in the same way. Available reports suggest that children and adolescents on injectable GLP-1 drugs are more likely to experience skin-related reactions like rash, hives, and hair loss, while facial fat redistribution has been described primarily in adults.¹⁷ This makes biological sense: younger skin has more collagen, more elasticity, and more resilience to bounce back from volume changes. The structural reserves that deplete with age are still intact in a teenager. That said, the pediatric data on GLP-1 drugs and skin effects is limited, and the absence of reported facial hollowing in young patients may partly reflect the fact that fewer adolescents have been studied for long enough periods.

For adults, one underappreciated factor is that Ozempic face is partly a problem of expectations. People who take these medications for diabetes management rather than weight loss tend to lose less weight and therefore experience less dramatic facial change. The most visible cases involve people who were using the drugs primarily for weight loss, often losing 15-20% or more of their starting weight. If you are on a GLP-1 agonist for blood sugar control and losing weight slowly, the odds of waking up one day to a dramatically altered face are much lower than the viral photos suggest.

1
PubMed. Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists
2
PubMed Central. Soft Tissue Facial Changes Following Massive Weight Loss Secondary to Medical and Surgical Bariatric Interventions: A Systematic Review
3
Dermatological Reviews. Semaglutide “Ozempic” Face and Implications in Cosmetic Dermatology
4
PubMed Central. GLP-1RA and the possible skin aging
5
Journal of Biomedical Science and Engineering. Investigating the Impact of GLP-1 Receptor Agonist-Induced Fat Loss on Collagen Synthesis and Skin Elasticity
6
Dermatologic Surgery. GLP-1–Induced Weight Loss and the Face: Anatomical Mechanisms and Rationale for Collagen-Stimulating and Volumizing Aesthetic Treatments
7
Brazilian Journal of Science. Weight loss from GLP-1 receptor agonists and facial ptosis: Specific mechanism or epiphenomenon of weight loss? A critical review
8
PubMed. Effects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review
9
PubMed Central. “Ozempic Face” in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions
10
PubMed Central. Soft Tissue Facial Changes Following Massive Weight Loss Secondary to Medical and Surgical Bariatric Interventions: A Systematic Review – Section: DISCUSSION
11
PubMed Central. Aesthetic Use of Poly-L-Lactic Acid and Hyaluronic Acid Fillers in Medication-Driven Weight Loss Due to GLP-1 Receptor Agonists: Real-World Case Series from Latin America
12
Aesthetic Surgery Journal. A Multicenter, Open-Label Study of Combined Poly-L-Lactic Acid and Hyaluronic Midface Filler Regimen Enhances Facial Harmony and Skin Quality in GLP-1 Medication Users
13
CosmoDerma. Semaglutide and the skin: A brief review of dermatologic implications
14
Journal of Cosmetic Dermatology. Mechanotransduction of Collagen Biostimulators: Comparative Signaling and Implications for GLP‐1 RA–Associated Facial Aging
15
PubMed. Validation of three-dimensional laser scanning for the assessment of facial fat changes
16
PubMed. Morphological changes of the human face after massive weight-loss due to bariatric surgery
17
Wiley Online Library (Pediatric Dermatology). Are Pediatric GLP-1 Receptor Agonist Cutaneous Adverse Events Being Overlooked? Emerging Age-Specific Patterns and Their Implications for Dermatologists